Tags Archive Navigation
icon
-
Media ReleaseNovartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
-
Media ReleaseNovartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience
-
Media ReleaseNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
-
Media ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
-
StoryToward regrowing cartilage
-
StoryThe search for new options for patients with lung cancer
-
StoryAdvancing medicine through collaboration
-
StoryNovartis and UC Berkeley take on “undruggable” proteins in new collaboration
-
StoryGuidance system lights a path for drug discovery
-
StoryDiscovery gives cystic fibrosis researchers new direction
-
StoryQ&A with new NIBR CIO Dimitris Agrafiotis